News
Eli Lilly’s Mounjaro gets marketing approval for weight-loss and diabetes treatment in India
US pharma giant Eli Lilly has secured Indian regulatory approval to market Mounjaro, its widely used diabetes and weight-loss drug. Available in six dosages, Mounjaro helps manage type 2 diabetes and chronic obesity by regulating blood sugar and appetite.
1don MSN
Eli Lilly and Company (NYSE: LLY) is one of the best Fortune 500 stocks to buy according to billionaires. On June 20, Eli ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
6don MSN
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...
inews.co.uk on MSN2d
No Mounjaro, GPs tell patients, unless you hit four criteria – and you’re very luckyGPs and pharmacists have warned it will be impossible to meet soaring demand for weight-loss jabs following their rollout on ...
Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...
Zacks Investment Research on MSN6d
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?Eli Lilly LLY signed a definitive agreement to acquire Verve Therapeutics VERV for a total deal value of nearly $1.3 billion.
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback